Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder clinically characterized by rapidly progressive paralysis and death due to respiratory failure, typically within two to three years of symptom onset. The number of ALS cases across the globe will increase to nearly 400,000 in 2040, predominantly due to aging of the population. Unraveling the genetics underlying ALS provides insights into the cellular mechanism leading to motor neuron death and provides targets for therapeutic intervention.
We performed a genome-wide association study involving a meta-analysis of 20,806 ALS cases and 59,804 controls. The current study release makes available genotype data of the 15,480 subjects assayed in the Laboratory of Neurogenetics for this effort.
- Study Weblinks:
- Study Design:
- Case-Control
- Study Type:
- Case-Control
- dbGaP estimated ancestry using GRAF-pop
- Total number of consented subjects: 15480
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
Inclusion criteria
All cases had been diagnosed with ALS according to the El Escorial criteria by a neurologist specializing in ALS, had onset of symptoms after age 18 years, and were of non-Hispanic white race/ethnicity. Patients with familial ALS and patients with sporadic ALS were included in the analysis. The control samples were obtained from individuals who were neurologically normal and did not carry a diagnosis of ALS. The control cohort was matched to the case cohort for race and ethnicity, but not for age or sex.
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Genome Genotyping Illumina HumanHap300v1.1 317503 33879 Previous Study Version Whole Genome Genotyping Illumina HumanHap250Sv1.0 241847 38544 Previous Study Version
Also referenced as HumanHap240Sv1.0Whole Genome Genotyping Illumina HumanHap550v3.0 561466 51468 Previous Study Version Whole Genome Genotyping Illumina HumanHap550v1.1 555352 38431 Previous Study Version Whole Genome Genotyping Illumina Human610_Quadv1_B 601273 1048904 Previous Study Version Targeted Region Genotyping Illumina iSelect Custom Panel 7100 N/A Previous Study Version Whole Exome Sequencing Illumina TruSeq Exome Enrichment Kit N/A N/A Previous Study Version Whole Exome Sequencing Illumina HiSeq 2000 N/A N/A Previous Study Version Whole Exome Sequencing Agilent SureSelect N/A N/A Previous Study Version Whole Exome Sequencing Roche NimbleGen SeqCap EZ Human Exome Library v1.0 N/A N/A Previous Study Version Whole Exome Sequencing Roche NimbleGen SeqCap EZ Human Exome Library v2.0 N/A N/A Previous Study Version Whole Genome Genotyping Illumina HumanOmniExpress-24 v1.0 N/A N/A Current Data Whole Genome Genotyping Illumina HumanOmniExpress-24 v1.1 N/A N/A Current Data - Study History
- June 2008 - Phenotype and analysis data were made available (genotype data are available through the Coriell Institute).
- May 2010 - Phenotype and genotype data were made available.
- April 2011 - Phenotype and genotype data of Italian study participants were made available.
- March 2014 - Case cohort exome sequencing data were made available.
- August 2018 - Phenotype and genotype/sequencing data of a total of n=15480 study participants now available.
All individual-level data are available through the dbGaP Authorized Access system by applying for study version 5 data.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Amyotrophic Lateral Sclerosis
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigators
- Bryan J. Traynor. National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
-
Funding Source
- Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
-
Funding Sources
- Z01-AG000933. National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigators